- Home
- MACI vs OABI Comparison
MACI vs OABI Comparison
Compare MACI & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MACI
- OABI
- Stock Information
- Founded
- MACI 2024
- OABI 2012
- Country
- MACI United States
- OABI United States
- Employees
- MACI N/A
- OABI N/A
- Industry
- MACI
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- MACI
- OABI Health Care
- Exchange
- MACI NYSE
- OABI Nasdaq
- Market Cap
- MACI 227.5M
- OABI 250.8M
- IPO Year
- MACI 2024
- OABI N/A
- Fundamental
- Price
- MACI $10.52
- OABI $2.12
- Analyst Decision
- MACI
- OABI Strong Buy
- Analyst Count
- MACI 0
- OABI 3
- Target Price
- MACI N/A
- OABI $7.00
- AVG Volume (30 Days)
- MACI 69.1K
- OABI 626.6K
- Earning Date
- MACI 01-01-0001
- OABI 08-06-2025
- Dividend Yield
- MACI N/A
- OABI N/A
- EPS Growth
- MACI N/A
- OABI N/A
- EPS
- MACI 0.33
- OABI N/A
- Revenue
- MACI N/A
- OABI $26,744,000.00
- Revenue This Year
- MACI N/A
- OABI N/A
- Revenue Next Year
- MACI N/A
- OABI $45.02
- P/E Ratio
- MACI $31.97
- OABI N/A
- Revenue Growth
- MACI N/A
- OABI 27.07
- 52 Week Low
- MACI $9.95
- OABI $1.22
- 52 Week High
- MACI $10.83
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- MACI N/A
- OABI 63.98
- Support Level
- MACI N/A
- OABI $1.90
- Resistance Level
- MACI N/A
- OABI $2.19
- Average True Range (ATR)
- MACI 0.00
- OABI 0.14
- MACD
- MACI 0.00
- OABI 0.00
- Stochastic Oscillator
- MACI 0.00
- OABI 65.35
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.